Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166837 | 1.00 | PAX8 (0.32) | PAX8 | |
| SCHEMBL19295 | 1.00 | PAX8 (0.32) | PAX8 | |
| Hydrochloric Acid SCHEMBL5913921 | 0.98 | PAX8 (0.31) | PAX8 | |
| Sulfuric Acid SCHEMBL9863900 | 0.98 | PAX8 (0.31) | PAX8 | |
| Hydrazine SCHEMBL1326324 | 0.98 | PAX8 (0.31) | PAX8 | |
| Hydrochloric Acid SCHEMBL1814659 | 0.97 | PAX8 (0.30) | PAX8 | |
| Hydrochloric Acid SCHEMBL6929597 | 0.97 | PAX8 (0.30) | PAX8 | |
| Hydrochloric Acid SCHEMBL1199579 | 0.97 | PAX8 (0.30) | PAX8 | |
| SCHEMBL3748924 | 0.94 | USP2 (0.36) | PAX8 | |
| SCHEMBL6475497 | 0.94 | USP2 (0.36) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022461-A1 | SULPHATED SUGARS TO INCREASE ACTIVITY OF SULPHATASES EN LYSOSOMAL STORAGE DISORDERS | CHILDREN, YOUTH AND WOMEN'S HEALTH SERVICE (AU) | 2010-03-04 | — | — | WO | claimed |
| US-20030162732-A1 | Combination of aminosugars and cysteine or cysteine derivatives | ASTION DEVELOPMENT A/S (DK) | 2003-08-28 | — | — | US | claimed |
| US-20030105034-A1 | Pyridine carboxy derivatives and an aminosugar | ASTION DEVEOPMENT A/S (DK) | 2003-06-05 | — | — | US | claimed |
| WO-2003002117-A2 | NIACIAMIDE AND DERIVATIVES IN COMBINATION WITH AMINOSUGAR | ASTION DEVELOPMENT A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002125-A2 | COMBINATION OF AMINOSUGARS AND CYSTEINE OR CYSTEINE DERIVATIVES | ASTION A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| US-9453040-B2 | Glycodendrimers of polypropyletherimine | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20150126468-A1 | GLYCODENDRIMERS OF POLYPROPYLETHERIMINE | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| WO-2012025744-A1 | GLYCODENDRIMERS OF POLYPROPYLETHERIMINE | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-03-01 | — | — | WO | disclosed |
| WO-2010022461-A1 | SULPHATED SUGARS TO INCREASE ACTIVITY OF SULPHATASES EN LYSOSOMAL STORAGE DISORDERS | CHILDREN, YOUTH AND WOMEN'S HEALTH SERVICE (AU) | 2010-03-04 | — | — | WO | disclosed |
| EP-1642574-A2 | Combination of a beta-2 adrenoceptor agonist and an aminosugar and their use for the treatment of immunomodulatory disorders | Astion Development A/S (DK) | 2006-04-05 | — | — | EP | disclosed |
| EP-1496917-B1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | ASTION DEV AS (DK) | 2005-12-07 | — | — | EP | disclosed |
| CN-1646143-A | Binding of beta-2 adrenoceptor agonists to aminosugars and their use in the treatment of immune disorders | ASTION DEV AS (DK) | 2005-07-27 | — | — | CN | disclosed |
| US-20050130935-A1 | Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders | ASTION DEVELOPMENT A/S (DK) | 2005-06-16 | — | — | US | disclosed |
| EP-1496917-A1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | Astion Development APS (DK) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003097073-A1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | ASTION DEVELOPMENT A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| US-20030162732-A1 | Combination of aminosugars and cysteine or cysteine derivatives | ASTION DEVELOPMENT A/S (DK) | 2003-08-28 | — | — | US | disclosed |
| US-20030105034-A1 | Pyridine carboxy derivatives and an aminosugar | ASTION DEVEOPMENT A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003002117-A2 | NIACIAMIDE AND DERIVATIVES IN COMBINATION WITH AMINOSUGAR | ASTION DEVELOPMENT A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002125-A2 | COMBINATION OF AMINOSUGARS AND CYSTEINE OR CYSTEINE DERIVATIVES | ASTION A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162732-A1 | Combination of aminosugars and cysteine or cysteine derivatives | CBS, CTH, AADAT | PAX8 2026/4885 |
| US-20030105034-A1 | Pyridine carboxy derivatives and an aminosugar | AADAT, CMA1, AASDHPPT | PAX8 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.